Global NASH Congress 2020

3rd Global NASH Congress is organized by Global Engage Ltd and will be held from Feb 10 - 11, 2020 at London Heathrow Marriott Hotel, London, England, United Kingdom.

Description:
Attracting experts working in all areas of nonalcoholic steatohepatitis, the conference will examine the latest research and development in pathogenesis, diagnosis, and treatment of the disease.

In order to stand out from the crowd, the meeting has been updated and expanded this year to explore Metabolic Syndrome, Diabetes and NAFLD and create a collaborative environment for these complementary research areas.

This two-day meeting has been purposely designed to facilitate collaboration and attract attendance from multiple stakeholders including KOL, investigators, academia, pharma, providers and regulators. The conference will examine the latest research and development in pathogenesis, diagnosis and treatment of the disease. As well as exceptional speaker presentations the meeting features 10 roundtable discussions. Each is led by an expert to provide you with a unique opportunity to debate the issues in areas such as the regulatory challenges for FDA approval, NASH and Diabetes and Preclinical models, to name just four.

The meeting will focus on several key themes:
• Regulatory Updates, Commercialization and Payor Perspective
• Optimising Preclinical & Translational Strategy / Models
• Non Invasive Biomarkers and Diagnostic Tools
• New targets for the treatment of NASH/ Fibrosis / NAFLD
• Recent updates in NASH Pathogenesis
• Emerging research and treatment areas - Novel targets and pathways, GLP-1 etc
• Clinical Development & Trial results / design / optimization
• Prevention and control / Nutrition and lifestyle
• Ties between obesity, diabetes and NAFLD
• Role of liver and NAFLD in insulin resistance and metabolic syndrome
• Organ communication between diseases

How You Will Benefit:
• Hear Key Opinion Leaders presentations
• Expert speakers from stakeholders in academia, pharma, biotech, regulators, payers, & providers
• Results from the latest phase 2/ 3 clinical trials
• Interactive roundtable discussions
• Foster collaboration specialists in NASH, Metabolic disease, Diabetes and NAFLD

Additional details will be posted as soon as information is available.